Antiviral activity of trappin-2 and elafin In vitro and In vivo against genital herpes

Journal of Virology

Volumn 87, Issue 13, 2013, Pages 7526-7538

  Drannik, Anna G ^a   Nag, Kakon ^b   Sallenave, Jean Michel ^c,d,e   Rosenthal, Kenneth L ^a,f,g  

^a MCMASTER UNIVERSITY   (Canada)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^c INSTITUT PASTEUR   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f MCMASTER UNIVERSITY   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; ELAFIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 8; SERINE PROTEINASE; SMALL INTERFERING RNA; TRAFFIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENITAL HERPES; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERINATAL CARE; PRIORITY JOURNAL; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; TRANSCYTOSIS; VAGINAL LAVAGE; VIRUS ATTACHMENT; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DNA PRIMERS; ELAFIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; INTERFERON REGULATORY FACTOR-3; INTERLEUKIN-8; MICE; MICE, TRANSGENIC; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VERO CELLS; VIRAL LOAD; VIRUS ATTACHMENT; VIRUS REPLICATION;

EID: 84880352306     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02243-12     Document Type: Article

References (82)

1. Chen CY, Ballard RC, Beck-Sague CM, Dangor Y, Radebe F, Schmid S, Weiss JB, Tshabalala V, Fehler G, Htun Y, Morse SA. 2000. Human immunodeficiency virus infection and genital ulcer disease in South Africa: the herpetic connection. Sex. Transm. Dis. 27:21-29.
2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.
3. Koelle DM, Wald A. 2000. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45(Suppl T3):1-8.
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83.
5. Corey L. 2007. Synergistic copathogens-HIV-1 and HSV-2. N. Engl. J. Med. 356:854-856.
6. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P. 2006. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 20:2305-2313.
7. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Kato H, Chen ZJ, Silverman RH, Akira S, Paludan SR. 2009. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible genelike receptors, which synergize to induce type I interferon production. J. Gen. Virol. 90:74-78.
8. Yu M, Levine SJ. 2011. Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev. 22:63-72.
9. Li H, Li X, Wei Y, Tan Y, Liu X, Wu X. 2009. HSV-2 induces TLRs and NF-kappaB-dependent cytokines in cervical epithelial cells. Biochem. Biophys. Res. Commun. 379:686-690.
10. Mogensen TH, Paludan SR. 2005. Reading the viral signature by Toll-like receptors and other pattern recognition receptors. J. Mol. Med. (Berl.) 83:180-192.
11. Kawai T, Akira S. 2006. Innate immune recognition of viral infection. Nat. Immunol. 7:131-137.
12. Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA. 2006. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J. Virol. 80:9943-9950.
13. Nazli A, Yao XD, Smieja M, Rosenthal KL, Ashkar AA, Kaushic C. 2009. Differential induction of innate anti-viral responses by TLR ligands against herpes simplex virus, type 2, infection in primary genital epithelium of women. Antiviral Res. 81:103-112.
14. Bauer CM, Dewitte-Orr SJ, Hornby KR, Zavitz CC, Lichty BD, Stampfli MR, Mossman KL. 2008. Cigarette smoke suppresses type I interferonmediated antiviral immunity in lung fibroblast and epithelial cells. J. Interferon Cytokine Res. 28:167-179.
15. Li Y, Li C, Xue P, Zhong B, Mao AP, Ran Y, Chen H, Wang YY, Yang F, Shu HB. 2009. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950.
16. Thapa M, Carr DJ. 2008. Herpes simplex virus type 2-induced mortality following genital infection is blocked by anti-tumor necrosis factor alpha antibody in CXCL10-deficient mice. J. Virol. 82:10295-10301.
17. Thapa M, Carr DJ. 2008. Chemokines and chemokine receptors critical to host resistance following genital herpes simplex virus type 2 (HSV-2) infection. Open Immunol. J. 1:33-41.
18. Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, Knipe DM, Finberg RW. 2005. The role of Toll-like receptors in herpes simplex infection in neonates. J. Infect. Dis. 191:746-748.
19. Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW. 2004. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl. Acad. Sci. U.S.A. 101:1315-1320.
20. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, Douglas MW. 2006. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194(Suppl1):S11-S18.
21. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R. 2007. Negative mucosal synergy between herpes simplex type 2 and HIV in the female genital tract. AIDS 21:589-598.
22. Ghosh M, Shen Z, Fahey JV, Cu-Uvin S, Mayer K, Wira CR. 2010. Trappin-2/elafin: a novel innate anti-human immunodeficiency virus 1 molecule of the human female reproductive tract. Immunology 129:207-219.
23. Iqbal SM, Ball TB, Levinson P, Maranan L, Jaoko W, Wachihi C, Pak BJ, Podust VN, Broliden K, Hirbod T, Kaul R, Plummer FA. 2009. Elevated elafin/trappin-2 in the female genital tract is associated with protection against HIV acquisition. AIDS 23:1669-1677.
24. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer RI, Herold BC. 2006. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177:8658-8666.
25. MasCasullo V, Fam E, Keller MJ, Herold BC. 2005. Role of mucosal immunity in preventing genital herpes infection. Viral Immunol. 18:595-606.
26. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM. 2005. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175:7560-7567.
27. Tsunemi M, Matsuura Y, Sakakibara S, Katsube Y. 1996. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution. Biochemistry 35:11570-11576.
28. Schalkwijk J, Wiedow O, Hirose S. 1999. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem. J. 340(Part 3):569-577.
29. Nara K, Ito S, Ito T, Suzuki Y, Ghoneim MA, Tachibana S, Hirose S. 1994. Elastase inhibitor elafin is a new type of proteinase inhibitor which has transglutaminase-mediated anchoring sequence termed "cementoin". J. Biochem. 115:441-448.
30. Drannik AG, Henrick BM, Rosenthal KL. 2011. War and peace between WAP and HIV: role of SLPI, trappin-2, elafin and ps20 in susceptibility to HIV infection. Biochem. Soc. Trans. 39:1427-1432.
31. Drannik AG, Nag K, Yao XD, Henrick BM, Ball TB, Plummer FA, Wachihi C, Kimani J, Rosenthal KL. 2012. Anti-HIV-1 activity of elafin depends on its nuclear localization and altered innate immune activation in female genital epithelial cells. PLoS One 7:e52738. doi:10.1371/journal.pone.0052738.
32. Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T. 2008. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J. 275:2008-2020.
33. Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T. 2005. Elafin and its precursor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 44:15610-15618.
34. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM. 1999. Elafin (elastase-specific inhibitor) has anti-microbial activity against Gram-positive and Gram-negative respiratory pathogens. FEBS Lett. 452:309-313.
35. Drannik AG, Nag K, Yao XD, Henrick BM, Sallenave JM, Rosenthal KL. 2012. Trappin-2/elafin modulate innate immune responses of human endometrial epithelial cells to polyI:C. PLoS One 7:e35866. doi:10.1371 /journal.pone.0035866.
36. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM. 2005. The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am. J. Respir. Cell Mol. Biol. 32:443-452.
37. Roghanian A, Williams SE, Sheldrake TA, Brown TI, Oberheim K, Xing Z, Howie SE, Sallenave JM. 2006. The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. Am. J. Respir. Cell Mol. Biol. 34:634-642.
38. King AE, Critchley HO, Sallenave JM, Kelly RW. 2003. Elafin in human endometrium: an antiprotease and antimicrobial molecule expressed during menstruation. J. Clin. Endocrinol. Metab. 88:4426-4431.
39. King AE, Paltoo A, Kelly RW, Sallenave JM, Bocking AD, Challis JR. 2007. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta 28:161-169.
40. Pfundt R, van Ruissen F, van Vlijmen-Willems IM, Alkemade HA, Zeeuwen PL, Jap PH, Dijkman H, Fransen J, Croes H, van Erp PE, Schalkwijk J. 1996. Constitutive and inducible expression of SKALP/ elafin provides anti-elastase defense in human epithelia. J. Clin. Invest. 98:1389-1399.
41. Pfundt R, Wingens M, Bergers M, Zweers M, Frenken M, Schalkwijk J. 2000. TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch. Dermatol. Res. 292:180-187.
42. Sallenave JM, Marsden MD, Ryle AP. 1992. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. Biol. Chem. Hoppe Seyler 373:27-33.
43. Schalkwijk J, de Roo C, de Jongh GJ. 1991. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim. Biophys. Acta 1096:148-154.
44. Wiedow O, Schroder JM, Gregory H, Young JA, Christophers E. 1990. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J. Biol. Chem. 265:14791-14795.
45. Fisman DN, Lipsitch M, Hook EW, III, Goldie SJ. 2002. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex. Transm. Dis. 29:608-622.
46. Simpson AJ, Cunningham GA, Porteous DJ, Haslett C, Sallenave JM. 2001. Regulation of adenovirus-mediated elafin transgene expression by bacterial lipopolysaccharide. Hum. Gene Ther. 12:1395-1406.
47. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC. 2008. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J. Virol. 82:9337-9344.
48. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. 1994. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase- specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. 11:733-741.
49. Drannik AG, Nag K, Yao XD, Henrick BM, Jain S, Ball TB, Plummer FA, Wachihi C, Kimani J, Rosenthal KL. 2012. Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells. J. Virol. 86:4599-4610.
50. Fichorova RN, Rheinwald JG, Anderson DJ. 1997. Generation of papillomavirus- immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissuespecific differentiation proteins. Biol. Reprod. 57:847-855.
51. Bett AJ, Haddara W, Prevec L, Graham FL. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U.S.A. 91:8802-8806.
52. Sallenave JM, Xing Z, Graham F, Gauldie J. 1997. In vivo adenovirusmediated expression of human pre-elafin, a potent neutrophil elastase inhibitor. Chest 111:128S-129S.
53. Sallenave JM, Xing Z, Simpson AJ, Graham FL, Gauldie J. 1998. Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. Gene Ther. 5:352-360.
54. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachihi C, Jaoko W, Plummer FA, Rosenthal KL. 2008. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS 22:685-694.
55. Sallenave JM, Cunningham GA, James RM, McLachlan G, Haslett C. 2003. Regulation of pulmonary and systemic bacterial lipopolysaccharide responses in transgenic mice expressing human elafin. Infect. Immun. 71:3766-3774.
56. Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stampfli MR. 2004. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 170:1164-1171.
57. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell. Microbiol. 6:401-410.
58. Murphy JA, Duerst RJ, Smith TJ, Morrison LA. 2003. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. J. Virol. 77:9337-9345.
59. Guo J, Peters KL, Sen GC. 2000. Induction of the human protein P56 by interferon, double-stranded RNA, or virus infection. Virology 267:209-219.
60. Mossman KL, Macgregor PF, Rozmus JJ, Goryachev AB, Edwards AM, Smiley JR. 2001. Herpes simplex virus triggers and then disarms a host antiviral response. J. Virol. 75:750-758.
61. Cook WJ, Kramer MF, Walker RM, Burwell TJ, Holman HA, Coen DM, Knipe DM. 2004. Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection. Virol. J. 1:5.
62. Corey L, Adams HG, Brown ZA, Holmes KK. 1983. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann. Intern. Med. 98:958-972.
63. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, Mc- Elvaney NG. 2006. Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway. J. Biol. Chem. 281:34730-34735.
64. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, Dorin JR, Sallenave JM. 2005. Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect. Immun. 73:3609-3617.
65. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5:730-737.
66. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM. 2004. Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J. Immunol. 172:4535-4544.
67. Nahmias AJ, Lee FK, Beckman-Nahmias S. 1990. Sero-epidemiological and -sociological patterns of herpes simplex virus infection in the world. Scand. J. Infect. Dis. Suppl. 69:19-36.
68. Koelle DM, Corey L. 2008. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 59:381-395.
69. Saidi H, Magri G, Nasreddine N, Requena M, Belec L. 2007. R5- and X4-HIV-1 use differentially the endometrial epithelial cells HEC-1A to ensure their own spread: implication for mechanisms of sexual transmission. Virology 358:55-68.
70. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild KT, Wahl S. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200:1337-1346.
71. Duffy CL, Phillips SL, Klingelhutz AJ. 2003. Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. Virology 314:196-205.
72. Duerst RJ, Morrison LA. 2004. Herpes simplex virus 2 virion host shutoff protein interferes with type I interferon production and responsiveness. Virology 322:158-167.
73. Yao XD, Rosenthal KL. 2011. Herpes simplex virus type 2 virion host shutoff protein suppresses innate dsRNA antiviral pathways in human vaginal epithelial cells. J. Gen. Virol. 92:1981-1993.
74. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, Low TB, O'Neill JS, McElvaney NG. 2005. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 202:1659-1668.
75. Chang TL, Vargas J, Jr, DelPortillo A, Klotman ME. 2005. Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. 115:765-773.
76. Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809.
77. Yoneyama M, Fujita T. 2010. Recognition of viral nucleic acids in innate immunity. Rev. Med. Virol. 20:4-22.
78. Hiscott J. 2007. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282:15325-15329.
79. Doehle BP, McNevin HFJP, McElrath MJ, Gale M, Jr. 2009. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J. Virol. 83:10.
80. Chan T, Barra NG, Lee AJ, Ashkar AA. 2011. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J. Reprod. Immunol. 88:210-218.
81. Duerst RJ, Morrison LA. 2007. Herpes simplex virus type 2-mediated disease is reduced in mice lacking RNase L. Virology 360:322-328.
82. Zaidi SH, Hui CC, Cheah AY, You XM, Husain M, Rabinovitch M. 1999. Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis. J. Clin. Invest. 103:1211-1219.